Annotation:
"Ethmozin" is the antiarrhythmic drug of choice for severe ventricular extrasystole. There are three different forms of the drug: tablets (coated), substance and substance (base, coating not specified by the manufacturer).
International nonproprietary name – Moracizine – active substance.
Indications for use. The drug is used to treat ventricular tachycardia and severe ventricular arrhythmia. Side effects. Various arrhythmic risks, cardiac arrest and vasodilatory effects, can lead to fatal intoxication in elderly patients, especially if they have additional symptoms of hypertension and diabetes. The active substance of this therapy increases tolerance to antipsychotic drugs, monoamine oxidase inhibitors and sedatives. However, combining these drugs with Ethmozin is not recommended. Due to the sedative ability of the drug, anesthesia and analgesia may be ineffective. The drug should not be prescribed to persons with hypersensitivity or atrioventricular block/bundle branch block. Contraindications: cardiogenic shock; hypotension, infarctions; kidney and liver failure; postpartum period with breastfeeding. There is no mention of an interaction in the literature, but it is known that Ethmosin-based monoamine oxidation inhibitors may increase the side effects of monoamine oxidase-inhibiting drugs. Therefore, they are prescribed together carefully. Overdose and special instructions are described in only one version of the encyclopedia. Given the intolerance of Ethmosin and its ability to alter circulation, fluid overload and nutrition must be taken into account. Interactions with other drugs are potentially unfavorable.